Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after ...
Fintel on MSN
Citigroup maintains DexCom (DXCM) buy recommendation
Fintel reports that on December 11, 2025, Citigroup maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.
Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
A Raymond James analyst cut his price target on the specialty medical device maker. It was the second such price target cut so far this month. Raymond James prognosticator Jayson Bedford was the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback